Clinical research in cardiometabolic diseases is defined by extraordinary complexity, with expanding global, biomarker‑intensive trials and rising regulatory and enrollment pressures. As innovation accelerates across GLP‑1 receptor agonists and next‑generation therapies and modalities, teams must manage increasing operational demands without compromising speed, data quality, or patient experience.
In this webinar, experts from Labcorp and Evido, will examine key scientific and operational challenges and show how early laboratory partnership and Labcorp’s global expertise improve efficiency and trial quality.
Webinar Highlights:
- Early biomarker strategy aligned to disease biology and endpoints
- Global assay and workflow harmonization for consistent data
- Broad and emerging biomarkers across inflammation, lipid metabolism, glycemic control, renal and hepatic injury
- Case studies on the role of innovative testing, particularly non-invasive tests, in improving patient identification and screen failure rates in MASH and obesity trials
- How laboratory insights, data, decentralized models and patient‑access networks improve diversity, access, and retention in cardiometabolic trials